Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biotechnology company focused on NK cell therapies for autoimmune diseases and cancers, Artiva uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and risk factors.
Recent Form 8-K filings highlighted in the available data include current reports on quarterly financial results, initial safety and translational data for AlloNK (AB-101) in autoimmune disease, and corporate matters such as amendments to the 2024 Equity Incentive Plan and equity award exchanges for certain executives. Other 8-Ks reference FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis and summarize clinical findings from ongoing Phase 1 and 2 trials combining AlloNK with anti-CD20 monoclonal antibodies after cyclophosphamide and fludarabine conditioning.
Through this page, users can review Artiva’s periodic reports, including 10-Q and 10-K filings, to understand research and development expenses, cash, cash equivalents and investments, net losses, and other financial information the company reports. AI-generated summaries can highlight key sections related to AlloNK’s clinical development, the CAR-NK oncology pipeline, the strategic partnership with GC Cell for NK cell manufacturing technology, and the company’s stated risk factors.
Investors can also reference proxy materials and equity plan amendments to see how Artiva structures compensation and equity incentives, as illustrated by the amendment to the 2024 Equity Incentive Plan approved at the 2025 Annual Meeting. Form 4 insider transaction reports, when available, can be used to monitor equity activity by directors and officers. Real-time updates from EDGAR combined with AI explanations help make ARTV’s regulatory record more accessible to readers who want to understand the company’s clinical, financial and governance disclosures in detail.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its Chief Tech Operations Officer. On 11/15/2025, 1,899 shares of common stock were withheld by the company at a price of $3.25 per share to cover income tax obligations tied to the vesting of restricted stock unit awards. After this tax withholding, the officer beneficially owns 78,183 shares of Artiva common stock in direct ownership. This filing is an administrative Form 4 disclosure of equity compensation and related tax settlement rather than an open-market buy or sell.
Artiva Biotherapeutics, Inc. (ARTV) reported an insider equity transaction by its COO, CLO, Secretary and Compliance Officer on a Form 4. On 11/15/2025, the officer had 3,055 shares of common stock withheld at a price of $3.25 per share. These shares were withheld by the company to cover income tax obligations associated with the vesting of restricted stock unit awards, rather than sold in an open-market transaction. After this tax withholding, the officer beneficially owned 148,048 shares of Artiva common stock directly.
Artiva Biotherapeutics, Inc. reported an insider equity transaction by its Chief Financial Officer, Neha Krishnamohan. On 11/15/2025, 3,490 shares of common stock were withheld by the company at a price of $3.25 per share to cover income tax obligations related to the vesting of restricted stock unit awards. After this tax withholding, the reporting person beneficially owns 99,356 shares of Artiva common stock directly.
Artiva Biotherapeutics (ARTV) President and CEO, who is also a director, reported routine equity transactions. On 11/15/2025, 6,347 shares of common stock were withheld by the company at $3.25 per share to cover income taxes from vesting restricted stock units. On 11/17/2025, the insider sold 6,375 shares of common stock at a weighted average price of $3.376 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on July 23, 2024. Following these transactions, the insider directly beneficially owned 343,999 shares of Artiva common stock.
Artiva Biotherapeutics (ARTV) disclosed initial safety and translational data for its investigational NK cell therapy AlloNK (AB-101) combined with rituximab or obinutuzumab in autoimmune diseases. As of October 1, 2025, 32 patients across refractory RA, Sjögren’s, systemic sclerosis, SLE and lupus nephritis were treated in outpatient settings, receiving 1B or 4B cells per dose. The regimen was generally well tolerated: no AlloNK-related Grade 3+ adverse events, no discontinuations, and no cytokine release syndrome, ICANS, GvHD or hypogammaglobulinemia; one hospitalization for an unrelated skin infection.
Translational findings showed all 23 analyzed patients had non-quantifiable peripheral CD19+ B cells by Day 13, corroborated by a high-sensitivity assay, with reconstitution patterns similar to CD19 auto-CAR-T. Artiva highlighted unmet need in refractory RA and plans to share initial clinical response data from >15 RA patients in H1 2026 and conduct FDA interactions in H1 2026 on a potential pivotal trial design.
Artiva Biotherapeutics (ARTV) reported Q3 2025 results marked by continued R&D investment and no product revenue. The company recorded a net loss of $21.5 million for the quarter and $63.1 million year‑to‑date. Q3 operating expenses were $22.9 million, driven by R&D of $17.6 million and G&A of $5.3 million. Net loss per share was $0.88 on 24.5 million weighted‑average shares.
Liquidity remained solid with $25.5 million in cash and cash equivalents and $97.5 million in short‑term investments, totaling $123.0 million as of September 30, 2025. The company used $62.0 million in cash for operating activities in the first nine months. Stockholders’ equity was $129.2 million, with total assets of $148.9 million. Management states existing cash, cash equivalents and investments will be sufficient to fund planned operations for at least one year from the issuance of these financial statements.
Artiva continues advancing NK cell programs, including AlloNK, under licensing and collaboration agreements with GC Cell. Shares outstanding were 24,544,904 as of October 31, 2025.
Artiva Biotherapeutics filed a Form 8‑K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The company notes the information under Item 2.02, including Exhibit 99.1, is furnished and not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless expressly stated.
Artiva Biotherapeutics (ARTV) reported an insider transaction on Form 4. The President & CEO and Director sold 25,500 shares of common stock at $6 on 10/17/2025. Following the sale, the reporting person beneficially owned 356,721 shares, held directly.
The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on July 23, 2024.
Fred Aslan, President, CEO and Director of Artiva Biotherapeutics (ARTV), reported three non-derivative stock transactions. On 05/15/2025 he had 4,472 shares withheld by the issuer to satisfy income tax obligations tied to RSU vesting at a price of $2.13, leaving 412,193 shares beneficially owned. On 08/15/2025 he sold 25,500 shares under a Rule 10b5-1 plan adopted July 23, 2024, at a weighted average sale price of $2.7286 (range $2.60–$2.80), reducing ownership to 386,693 shares. Also on 08/15/2025 another 4,472 shares were withheld for taxes at $2.75, resulting in 382,221 shares owned. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Raymon Heather, SVP, Research and Development of Artiva Biotherapeutics, Inc. (ARTV), reported two dispositions of common stock tied to restricted stock unit vesting tax-withholdings. On 05/15/2025 the issuer withheld 745 shares at an effective price of $2.13, leaving 42,605 shares beneficially owned. On 08/15/2025 an additional 1,639 shares were withheld at $2.75, leaving 40,966 shares.
The Form 4 was executed by an attorney-in-fact and discloses these routine withholding transactions to satisfy income tax obligations associated with RSU vesting. No derivatives, option exercises, or other types of transactions are reported, and the filing indicates direct ownership by the reporting person.